DBV Technologies is advancing its pursuit of U.S. regulatory approval for VIASKIN Peanut, an epicutaneous immunotherapy patch designed to desensitize young children to peanut allergies. The company disclosed the progress during a presentation at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026.
CEO Daniel Tassé said DBV has completed its pivotal clinical trials and is in advanced discussions with the Food and Drug Administration regarding its biologics license application. The conversations are focused on Module 3 chemistry, manufacturing and controls documentation, along with clinical data organization and the biostatistics package. The patch holds active breakthrough therapy designation.
VIASKIN Peanut delivers a daily dose of 250 micrograms — or 150/250 micrograms depending on patient — of peanut protein through the skin, roughly one-thousandth of a peanut kernel. The mechanism relies on Langerhans cells and a Treg-modulated immune response, eliminating the need for the dose escalation required by oral immunotherapy approaches.
In three-year cohort data, 68.2% of children using VIASKIN Peanut were able to tolerate a whole food challenge equivalent to 12 to 14 peanuts worth of peanut protein without an allergic reaction. Tassé described the result as "seven out of 10 kids."
The addressable U.S. market centers on children ages 1 to 7 with peanut allergies, a population estimated at roughly 600,000 — about 100,000 children per annual birth cohort, according to epidemiology researcher Dr. Ruchi Gupta of Northwestern University. Prevalence sits at 1.8% to 2.2% of that age group, unchanged over a decade of surveys.
DBV's pipeline includes the THRIVE study, which will enroll infants aged 6 to 12 months and treat them with VIASKIN Peanut for three to four years in a trial expected to span roughly five years. The patch is being studied across two initiation-age cohorts: children aged 1 to 3 and those aged 4 to 7.
The competitive landscape features Aimmune Therapeutics' Palforzia, an oral immunotherapy product. Only about 100 of the approximately 4,500 allergists in the U.S. practice oral immunotherapy at scale, and Xolair use among children ages 1 to 7 with peanut allergies is estimated at just 1%, according to Tassé.
DBV's current valuation stands at approximately €1.3 billion to €1.4 billion. The company has sufficient cash for roughly one year and expects to raise additional capital to fund commercialization. Shares have declined 31% year-to-date and 42% over the prior six months, though they are up 41% over the past year. Analyst price targets range from $5.91 to $55.91.
Tassé founded DBV as a biotech spun from the work of two French academics who identified the skin as a powerful immune organ capable of enabling allergy desensitization. He characterized VIASKIN Peanut's value proposition as sitting at the intersection of convenience, efficacy and safety, comparing the product's role to that of an airbag — a safeguard rather than a cure.
